MedTrace Logo

Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia

NCT04535063 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-07-19

No results posted yet for this study

Summary

To determinate feasibility, safety and outcome with convalescent plasma in patients with severe COVID-19 penumonia

Conditions

  • Covid19 Pneumonia

Interventions

BIOLOGICAL

COVID19 convalescent plasma infusion

intravenous infusion of 300-600 mL of convalescent plasma with an antibody title more than 3 according to chemiluminescent microparticle immunoassay (Architect Plus Abbott)

Sponsors & Collaborators

  • Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-18
Primary Completion
2020-12-30
Completion
2021-02-25

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04535063 on ClinicalTrials.gov